Reunion Neuroscience Inc. to Participate in October Investor Conferences

WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1 meeting with the company.

About Reunion Neuroscience Inc.

Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being investigated as a potential treatment for postpartum depression that could provide rapid symptom relief and durable efficacy. RE104 is protected under U.S. Patent No. 11,292,765 issued on April 5, 2022 (priority June 30, 2020), with claims for composition of matter, methods of manufacturing, formulations and methods of use for a genus of hemiester tryptamines, including RE104, which could provide protection out to June 30, 2041. Reunion is also developing the RE200 series, which includes preclinical compounds designed with enhanced receptor selectivity to address additional therapeutic applications.

For further information:

Investor Contacts:Irina KofflerLifeSci Advisors, LLC646.970.4681[email protected]

You May Also Be Interested In

• Information regarding executed transactions within the framework of a share buyback programme (outside the liquidity agreement) from 10 August to 14 August 2026
• Milton Hydro Launches Two-Year Pilot Program of G&W Electric’s Safegrid Intelligent Grid System to Enhance Grid Reliability
• Purple Heart Homes Launches Historic National Mall Veteran Home Build During America's 250th Anniversary